NewslettersIntestinal Cell NewsErasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate Eras-007 and Encorafenib CombinationBy Jamie Kang - December 1, 20220154Erasca, Inc. announced a clinical trial collaboration and supply agreement with Pierre Fabre for the BRAF inhibitor encorafenib, BRAFTOVI®, within key international territories.[Erasca, Inc.]Press Release